Physician profile
Robert A Burger
NPI 1043393564
$58,866.37
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $10K · 2021: $9,925.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36,319.23 | 2019-2021 | |
| Tesaro, INC. | $15,586.15 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $3,250.28 | 2019 | |
| Myriad Genetic Laboratories, INC. | $1,500.00 | 2020 | |
| Merck Sharp & Dohme LLC | $1,000.00 | 2019 | |
| Eisai INC. | $691.67 | 2019 | |
| Genentech, INC. | $472.42 | 2020 | |
| Roche Products Limited | $37.50 | 2019 | |
| Clovis Oncology, INC. | $9.12 | 2020 |
3 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Burger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.